A Long-term Treatment With B-VEC for Dystrophic Epidermolysis Bullosa
Completed · Phase 3 · NCT04917874
Conditions: Dystrophic Epidermolysis Bullosa, DEB - Dystrophic Epidermolysis Bullosa, Recessive Dystrophic Epidermolysis Bullosa, Dominant Dystrophic Epidermolysis Bullosa
At a glance
- Research payments reported, 2025
- $4,500
- U.S. investigators named
- 1
- Sites paid
- 1
- Planned or actual enrollment
- 47
About the trial
- Sponsor
- Krystal Biotech, Inc.
- Tested
- Open Label Topical Beremagene Geperpavec (B-VEC) (biological)
- Dates
- Started 2021-05-25; completion 2023-07-31
- Results posted
- Not yet
This is a 112-week (approximately two-year) open-label extension study of Beremagene Geperpavec (B-VEC), for participants aged 2 months and older, who have been diagnosed with Dystrophic Epidermolysis Bullosa (DEB). Participants will be dosed weekly with the topical B-VEC therapy. The primary endpoint will be to assess long term safety and tolerability of the topical gene therapy. The study is for those who participated in Phase 3 study, as well as, new participants who were unable to participate in the Phase 3 study, who meet all enrollment criteria.
From ClinicalTrials.gov, last updated 2024-04-09. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Krystal Biotech Inc reported $4,500 in research payments for this study in 2025 (1 payments).
Products named: Vyjuvek
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Ascension Seton $4,500
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.